UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000005864
Receipt number R000006928
Scientific Title Clinical research of atorvastatin to evaluate the effect of OATP2B1 inhibition
Date of disclosure of the study information 2011/06/28
Last modified on 2011/12/28 10:16:25

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Clinical research of atorvastatin to evaluate the effect of OATP2B1 inhibition

Acronym

Atorvastatin-drug interaction through inhibition of OATP2B1

Scientific Title

Clinical research of atorvastatin to evaluate the effect of OATP2B1 inhibition

Scientific Title:Acronym

Atorvastatin-drug interaction through inhibition of OATP2B1

Region

Japan


Condition

Condition

healthy male

Classification by specialty

Adult

Classification by malignancy

Others

Genomic information

YES


Objectives

Narrative objectives1

To assess inhibitory effect of atorvastatin on OATP2B1 in healthy volunteer, which was screened by SLCO2B1 genotype.

Basic objectives2

Pharmacokinetics

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

PK profiles of celiprolol, fexofenadine and atorvastatin

Key secondary outcomes



Base

Study type

Interventional


Study design

Basic design

Cross-over

Randomization

Randomized

Randomization unit

Individual

Blinding

Open -no one is blinded

Control

No treatment

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

2

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

celiprolol and atorvastatin, wash out, fexofenadine and atorvastatin

Interventions/Control_2

fexofenadine and atorvastatin, wash out, celiprolol and atorvastatin

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit

45 years-old >=

Gender

Male

Key inclusion criteria

the investigors must ensure that all subjects
being considerd meet the following inclusion
criteria:
1) Japanese healthy male who is capable to
understand and sign the
informed consent.
2) 20-45 years of age
3)BMI 18.5-25.0
4)good health as determined by physical
examination, vital signs and laboartory tests.

Key exclusion criteria

the investigors must ensure that all subjects
being considerd meet the following exclusion
criteria or conditions:
1)history of allergy to any drugs
2)medical attention within 2 months prior to
participation
3)donation of 200mL or more of blood within
4 weeks prior to participation,
or donation of component blood within 2
weeks prior to participation
4)donation of 400mL or more of blood within
12 weeks prior to participation
5)recent (past 4 months) participation in
other clinical trial for investigational new
chemical entity
6)history of drug abuse
7)alcohol abuse

Target sample size

16


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Shin Irie

Organization

LTA

Division name

Kyusyu Clinical Pharmacology Clinic

Zip code


Address

2-13-16 Jigyo Fukuoka

TEL


Email



Public contact

Name of contact person

1st name
Middle name
Last name

Organization

LTA

Division name

Kyusyu Clinical Pharmacology Clinic

Zip code


Address


TEL

092-733-1001

Homepage URL


Email



Sponsor or person

Institute

Department of clinical pharmacokinetics, Kyushu University

Institute

Department

Personal name



Funding Source

Organization

Trust Account of Kyushu University

Organization

Division

Category of Funding Organization

Other

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2011 Year 06 Month 28 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2011 Year 06 Month 09 Day

Date of IRB


Anticipated trial start date

2011 Year 06 Month 01 Day

Last follow-up date


Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2011 Year 06 Month 28 Day

Last modified on

2011 Year 12 Month 28 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000006928


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name